- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- SlideSet RA
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheuma»
ACR 2017 | Daily Highlights
Comparison of Clinical and Ultrasound Measures of Disease Activity in a Large National ‘Real Life’ Cohort of RA Patients
Authors: Pascal Zufferey1, Delphine Couvoisier2, Hans Ruedi Ziswiler3, Laure Brulhart4, Giorgio Tamborrini5, Michael Nissen6, Adrian Ciurea7, Burkhard Moeller8, Maria Antonietta D'Agostino9,10 and Axel Finckh2, 1Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, 2geneva university hospital, Geneva, Switzerland, 3Osteorheuma, Bern, Switzerland, 4médecine, hôpital neuchateulois, La chaux de fond, Switzerland, 5UZR, Basel, Switzerland, 6rheumatology, geneva university hospital, Geneva, Switzerland, 7Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 8Department for Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland, 9Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, 10University of Paris, Paris, France
Clinical measures of disease activity, such as the DAS-score and ultrasound (US) scores of disease activity can be sometimes yield discordant results. Little research has attempted to understand the reasons for these discordances. Moreover, it is not well known what the implications of such discordances are or how clinical and US assessments evolve over time in this situation
First: to determine the percentages of patients presenting discordances between DAS and US assessments in a real-life cohort. Second: to describe associated factors. Third: to evaluate the evolution of both measures of disease activity over time.
All patients with at least one concomitant US- and DAS-score assessment, performed since the introduction of validated US (SONAR) score in the SCQM between 2009 and January 2017 were included. Disease activity was categorized as remission, low, moderate and high activity based on previously established cut-offs for the DAS and the US-score. Potential predictors of discordance were extracted from the SCQM database, including age, gender, seropositivity, duration of illness, number of swollen and tender joints, global physician assessment of disease activity, HAQ, presence of fibromyalgia, type of treatment, patients followed in private practice and other. A longitudinal analysis was performed in all the patients with at least two subsequent visits with US and DAS assessment performed simultaneously
2367 assessments could be analyzed, of which 1072 (45%) were considered concordant based on identical disease activity states with the DAS- and the US score. The proportion concordant assessments significantly differed by clinical disease status (p<0.001); more frequent in clinical remission (78.4% of agreement) compared to active disease status (21% in low or moderate DAS, 45% in high DAS). Among the discordant assessments, disease activity state tended to be more frequently over-estimated by the DAS compared to US-score (38%), than the other way round (17%), (p<0.05).
Factors associated with the presence of discordant results were the swollen joint count (p <0.001), the overall estimation of the disease activity (p<0.001) by the clinician, the duration of the disease (p<0.02)
For 1181 patients, several DAS and US assessments were available during follow-up. The proportion of discordances during the follows up was similar to the initial evaluation. Initial discordance/concordances could however change status without obvious reason, especially in the moderate and low disease activity subgroup (75 % new discordances).
Discordances between DAS and US assessments appear to be higher than expected in real life. Both outcome measures can lead to over- or under-estimations of the true disease activity, Discordant assessments seem to be linked essentially to inaccuracies in the clinical evaluation in particular (inadequate swollen joint counts) and /or to limitations of the US procedure (especially poor distinction between moderate and low activity disease.
P. Zufferey, None; D. Couvoisier, None; H. R. Ziswiler, None; L. Brulhart, None; G. Tamborrini, None; M. Nissen, None; A. Ciurea, None; B. Moeller, None; M. A. D'Agostino, None; A. Finckh, None.
Pascal Zufferey and colleagues compared the DAS-score and ultrasound (US) scores of disease activity in the SCQM cohort.
Concordance was more frequent in clinical remission (78.4% agreement) compared to active disease status (21% in low or moderate DAS, 45% in high DAS). The swollen joint count (p <0.001) and the overall estimation of the disease activity (p<0.001) by the clinician were associated with discordance.
These findings suggest a cautious approach to assessing disease activity based on the one or other approach. Rather, the results of both need to be evaluated carefully for their impact on clinical decision making, especially when ultrasound measures are used to distinguish between low and moderate disease activity.
Prof. Dr. Paul Hasler